Neuranics Secures $700,000 Seed Funding to Transform Blood Diagnostics

The investment will support the development and clinical validation of the company’s cutting-edge blood diagnostics technology.

Healthcare diagnostics startup Neuranics has raised $700,000 in a seed funding round led by Inflection Point Ventures (IPV).

The investment will support the development and clinical validation of the startup’s cutting-edge blood diagnostics technology, which aims to revolutionize the field with faster, more efficient solutions.

Point-of-Care Blood Analyzer for Rapid Results

At the heart of Neuranics’ innovation is a compact, point-of-care blood analyzer capable of delivering complete blood count (CBC) results in under 10 minutes from a simple finger-prick sample.

This device is designed for use in primary care and emergency settings, offering low maintenance and high efficiency.

The technology eliminates delays associated with traditional blood testing, which often requires transporting samples to centralized laboratories.

With Neuranics’ analyzer, healthcare providers can access accurate CBC results while still consulting with patients, enabling faster decision-making for triage, diagnosis, and treatment.

The analyzer is particularly valuable in addressing urgent conditions such as sepsis, severe anemia, and thrombocytopenia in dengue patients, where timely intervention can be life-saving.

Additionally, it helps reduce healthcare costs by minimizing unnecessary treatments, such as inappropriate antibiotic use, while ensuring patients receive the care they need without delays.

Dr Megha Sharma, Chief Medical Evangelist at Neuranics, emphasized the transformative nature of the technology, “By utilizing a simple finger-prick capillary blood sample, we have eliminated the need for traditional venipuncture. This makes blood testing faster, less invasive, and more patient-friendly. Our technology empowers healthcare providers to deliver immediate insights, especially in resource-limited settings like primary health centers and emergency setups.”

The startup’s patented dry hematology design delivers precise results directly at the point of care, making it uniquely positioned to address urgent diagnostic needs.

Neuranics has already made significant strides, receiving a patent, a CDSCO Test License, and ethical approval from AIIMS Delhi. The startup is currently progressing through clinical trials, further validating its technology.

Empowering Clinicians with Real-Time Data

Praveen Kumar, Co-founder and CEO of Neuranics shared the startup’s vision, “We are reimagining diagnostics by bringing instant, accurate blood analysis closer to the patient without compromising on quality. Our technology empowers clinicians with real-time data, transforming care delivery and elevating patient outcomes.”

Kumar also highlighted Neuranics’ commitment to leveraging AI for advancing healthcare.

By analyzing de-identified pathological imaging data generated by their analyzer, the startup aims to set a new standard for national screening programs, enhancing healthcare quality and establishing India as a leader in point-of-care diagnostics.

Neuranics operates in the thriving diagnostics industry, with the global CBC market projected to reach $50 billion, growing at a compound annual growth rate (CAGR) of 8-10%.

Stay tuned for more such updates on Digital Health News.